	Search News Daily News

NEWS

Daily News Top Stories Breaking News World Politics Business Growth Minute Health Breast Cancer Food & Wine Women Women in Business Opinion Letters to the Editor High Tech Sports Horoscope Entertainment Entertainment Goss Music Features Books Poetry Movie Reviews Home & Garden Industry States Health Column Senior Health Environment Education SupportOurTroops Middle East South Asia Cartoons Video Releases Most Read

WIRES

Eworldwire Marketwire GlobeNewswire PRNewswire Send2Press Marketwire Canada 24-7 Pressrelease Realwire PR.com ACNNewswire Business Wire NewsBlazeWire Spanish Releases Movers/Shakers

OTHER

About Us Contact Us Feedback Writers Bookmarks Link to Us Advertise Sitemap

TECHNOLOGY

RFID Supply Chain Text to Speech Voice Over IP Wi-Fi Games iPod Biotech

NEWSPAPERS

Folsom Orange County Boca Raton St Augustine Vero Beach

Breaking News: Tea Party Against Reid Health Care Bill

Published:

Send to a friend

Rexin-G Controls Tumor Growth and Improves Survival in Chemotherapy-Resistant Soft Tissue Sarcoma and Osteosarcoma

Phase I/II & Confirmatory Phase II Studies

SAN MARINO, Calif., Nov. 20 (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies announced today the results of Phase I/II and II studies of Rexin-G in chemotherapy-resistant metastatic soft tissue sarcoma and osteosarcoma, as presented by Dr. Sant P. Chawla, principal investigator, at the CTOS 14th annual meetings held in London UK on November 13-15, 2008. Patients received repeated infusions of Rexin-G i.v. over a period up to 9 months. Analysis of safety and efficacy data showed no major toxicity, while documenting significant control of tumor growth.

epeius Analysis of efficacy in 42 patients with bone and soft tissue sarcoma showed a dose-response relationship between overall survival and Rexin-G which was highly significant. A confirmatory Phase II study in 17 osteosarcoma patients showed a median overall survival greater than seven months; that is, after failing standard chemotherapies.

Two patients are disease-free greater than 6 months after surgical resection of residual tumors and Rexin-G given as both neoadjuvant and adjuvant monotherapy.

These studies indicate that (i) intravenous Rexin-G is safe and well-tolerated, and (ii) Rexin-G controls tumor growth and improves survival in a dose-dependent manner in patients with chemotherapy-resistant metastatic soft tissue sarcoma and osteosarcoma.

About Epeius Biotechnologies

Epeius Biotechnologies Corporation is a privately held biopharmaceutical company dedicated to the advancement of genetic medicine with the development and commercialization of its proprietary targeted delivery systems.

To learn more about Rexin-G® and Epeius Biotechnologies' pipeline of proprietary compounds currently available for clinical development, please visit us at www.epeiusbiotech.com.

Copyright © 2008 Send2Press® Newswire, a unit of Neotrope®
TAGS: Send2Press Newswire, Epeius Biotechnologies Rexin-G, chemotherapy resistant metastatic cancers

Copyright © 2009, NewsBlaze, Daily News

Tags: ,Drugs and Pharmaceuticals,Send2Press,,,

Be Interviewed today

Editorial Cartoons
Political Cartoons

<style> /* RESET STYLES */ .fxw hr,.fxw div,.fxw span,.fxw h1,.fxw h2,.fxw h3,.fxw p,.fxw a,.fxw em,.fxw img,.fxw strong,.fxw ol,.fxw ul,.fxw li {margin: 0;padding: 0;border: 0;outline: 0;font-weight: inherit;font-style: inherit;font-size: 100%;font-family: inherit;vertical-align: baseline;line-height: 1;list-style: none; } .fxw {font-family: Arial, sans-serif !important;font-size: 11px !important;border: 1px solid #004c00;background-color: #fff;position: relative !important;} .fxw .clear {clear: both !important;height: 1px !important;overflow: hidden !important; } /* Header */ .fxw_header {color: #fff;background: #004c00;padding: 10px !important;font-weight: bold !important;font-size: 14px !important;} /* Footer */ .fxw_footer {color: #fff;background: #004c00;padding: 10px !important;} .fxw_footer a{text-decoration: none !important;font-weight: bold !important;color: #fff;} .fxw_footer .fxw_pipe {padding: 0px 3px 0px 3px;} /* Body */ .fxw_body {padding: 10px !important;overflow: auto !important; } /* Story Item */ .fxw_story {border-bottom: 1px solid #e3e3e3 !important;padding-bottom: 8px !important;margin-bottom: 8px !important;} .fxw_story.fxw_last {border: 0px !important;} .fxw_story.fxw_image {padding-left: 60px !important;} .fxw_story.fxw_image img {float: left;width: 50px;margin: 0px 0px 0px -60px;} /* Story Title */ .fxw_title {margin: 0px !important;padding: 0px !important;} .fxw_title a {text-decoration: none !important;font-weight: bold !important;font-size: 12px !important;line-height: 16px !important;color: #000099; } /* Story Description */ .fxw_desc {color: #666;padding: 0px !important;margin: 1px 0px 0px 0px !important;line-height: 14px !important;font-size: 11px !important;} /* Story Image */ img.fxw_image {width: 35px !important;height: 35px !important;margin: 2px 0px 0px -45px !important;float: left !important;} </style> <script type="text/javascript"> fxw_city = ''; fxw_limit = 6; fxw_source = ''; fxw_topic = ''; fxw_id = 'fxw_container'; fxw_target = '_blank'; fxw_showImage = false; fxw_showDescription = false; fxw_customCSS = true; </script> <script type="text/javascript" src="http://fwix.com/tools/widget/v1"></script> <a href="http://fwix.com" id="fxw_clear"><img src="http://fwix.com/images/clear.gif" border="0" title="Fwix - Your New Local Newspaper" /></a>

NewsBlaze on Twitter
NewsBlaze on Facebook
NewsBlaze on MySpace

Sponsor Links:

Writers Wanted

Help NewsBlaze provide daily news, including top stories, Home and Garden, Technology, The Environment and more. NewsBlaze Writer

Relevant Sites:

NewsBlaze

Copyright © 2004-2009 NewsBlaze LLC
Use of this website is subject to our Terms of Service and Privacy Policy Support Press Room